JP2019526559A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019526559A5 JP2019526559A5 JP2019510651A JP2019510651A JP2019526559A5 JP 2019526559 A5 JP2019526559 A5 JP 2019526559A5 JP 2019510651 A JP2019510651 A JP 2019510651A JP 2019510651 A JP2019510651 A JP 2019510651A JP 2019526559 A5 JP2019526559 A5 JP 2019526559A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- combination drug
- mek inhibitor
- drug according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024125935A JP2024170398A (ja) | 2016-08-23 | 2024-08-01 | 膵がん治療のための組み合わせ治療薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378322P | 2016-08-23 | 2016-08-23 | |
| US62/378,322 | 2016-08-23 | ||
| PCT/US2017/047985 WO2018039211A1 (en) | 2016-08-23 | 2017-08-22 | Combination therapy for the treatment of pancreatic cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024125935A Division JP2024170398A (ja) | 2016-08-23 | 2024-08-01 | 膵がん治療のための組み合わせ治療薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019526559A JP2019526559A (ja) | 2019-09-19 |
| JP2019526559A5 true JP2019526559A5 (enExample) | 2020-10-01 |
| JP7579636B2 JP7579636B2 (ja) | 2024-11-08 |
Family
ID=59762090
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019510651A Active JP7579636B2 (ja) | 2016-08-23 | 2017-08-22 | 膵がん治療のための組み合わせ治療薬 |
| JP2024125935A Pending JP2024170398A (ja) | 2016-08-23 | 2024-08-01 | 膵がん治療のための組み合わせ治療薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024125935A Pending JP2024170398A (ja) | 2016-08-23 | 2024-08-01 | 膵がん治療のための組み合わせ治療薬 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10933058B2 (enExample) |
| EP (1) | EP3503922B1 (enExample) |
| JP (2) | JP7579636B2 (enExample) |
| KR (1) | KR20190039951A (enExample) |
| CN (1) | CN109641058A (enExample) |
| AU (1) | AU2017316618A1 (enExample) |
| BR (1) | BR112019002945A2 (enExample) |
| CA (1) | CA3034259A1 (enExample) |
| IL (1) | IL264589A (enExample) |
| MX (1) | MX2019002121A (enExample) |
| WO (1) | WO2018039211A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3034259A1 (en) * | 2016-08-23 | 2018-03-01 | Genentech, Inc. | Combination therapy for the treatment of pancreatic cancer |
| US20210220471A1 (en) * | 2018-07-13 | 2021-07-22 | Memorial Sloan Kettering Cancer Center | Methods of using pharmacologic inhibitors of type 2 cytokine signaling to treat or prevent pancreatic cancer |
| US20210113564A1 (en) * | 2019-10-22 | 2021-04-22 | Chemistryrx | Methods for treating congenital epidermal hyperplasia and compositions for same |
| JP2023518132A (ja) * | 2020-03-06 | 2023-04-27 | ベイジン・シノタウ・バイオ－ファーマシューティカルズ・テクノロジー・カンパニー，リミテッド | Ｃｔｂ００６とポナチニブとの併用の適用 |
| CN115813930A (zh) * | 2021-08-17 | 2023-03-21 | 赛诺哈勃药业（成都）有限公司 | 大环化合物与mek抑制剂联用在用于治疗疾病药物中的用途 |
| CN115838720A (zh) * | 2022-07-28 | 2023-03-24 | 吉林启众生物科技有限公司 | 一种携带shSTAT3/shPD-L1重组质粒的减毒沙门氏菌载体及其应用 |
| CN116509852A (zh) * | 2023-04-30 | 2023-08-01 | 兰州大学第二医院 | 含zinc218238819化合物的胰腺癌jak2和stat3双靶向抑制剂及应用 |
| CN116585312A (zh) * | 2023-04-30 | 2023-08-15 | 兰州大学第二医院 | 含苯氧基丙酸化合物的胰腺癌jak2和stat3双靶向抑制剂及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US9532987B2 (en) * | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| WO2015175846A2 (en) * | 2014-05-16 | 2015-11-19 | University Of Massachusetts | Treating chronic myelogenous leukemia (cml) |
| WO2016123054A2 (en) * | 2015-01-26 | 2016-08-04 | The University Of North Carolina At Chapel Hill | Kinase drug combinations and methods of use thereof |
| EP3256473A4 (en) * | 2015-02-12 | 2018-08-01 | Memorial Sloan Kettering Cancer Center | Synergistic cancer treatment |
| CA3034259A1 (en) * | 2016-08-23 | 2018-03-01 | Genentech, Inc. | Combination therapy for the treatment of pancreatic cancer |
-
2017
- 2017-08-22 CA CA3034259A patent/CA3034259A1/en not_active Abandoned
- 2017-08-22 WO PCT/US2017/047985 patent/WO2018039211A1/en not_active Ceased
- 2017-08-22 MX MX2019002121A patent/MX2019002121A/es unknown
- 2017-08-22 CN CN201780051187.XA patent/CN109641058A/zh active Pending
- 2017-08-22 JP JP2019510651A patent/JP7579636B2/ja active Active
- 2017-08-22 BR BR112019002945-1A patent/BR112019002945A2/pt not_active IP Right Cessation
- 2017-08-22 KR KR1020197004431A patent/KR20190039951A/ko not_active Ceased
- 2017-08-22 EP EP17761408.8A patent/EP3503922B1/en active Active
- 2017-08-22 AU AU2017316618A patent/AU2017316618A1/en not_active Abandoned
-
2019
- 2019-01-31 IL IL264589A patent/IL264589A/en unknown
- 2019-02-22 US US16/283,203 patent/US10933058B2/en active Active
-
2021
- 2021-02-19 US US17/180,522 patent/US12419879B2/en active Active
-
2024
- 2024-08-01 JP JP2024125935A patent/JP2024170398A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019526559A5 (enExample) | ||
| KR20170084034A (ko) | 암 치료용 의약 조성물 제조에서의 아젤니디핀의 용도 | |
| JP2019065028A5 (enExample) | ||
| MX2021009199A (es) | Conjugado de farmaco de dos ligandos y uso del mismo. | |
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| JP2009539769A5 (enExample) | ||
| Frieboes et al. | Chloroquine-mediated cell death in metastatic pancreatic adenocarcinoma through inhibition of autophagy | |
| FI3493812T3 (fi) | Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten | |
| JP2016515586A5 (enExample) | ||
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| JP2019530706A5 (enExample) | ||
| JP2012107063A5 (enExample) | ||
| IL259512B2 (en) | Combination for the effective treatment of metastatic cancer in patients | |
| Choy et al. | SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine‐Containing Therapy | |
| JP2017503846A5 (enExample) | ||
| Peng et al. | Thermosensitive injectable hydrogel enhances the antitumor effect of embelin in mouse hepatocellular carcinoma | |
| JP2014504636A5 (enExample) | ||
| Wang et al. | Homoharringtonine: mechanisms, clinical applications and research progress | |
| JP2021505669A5 (enExample) | ||
| JP2013540734A5 (enExample) | ||
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| RU2015115398A (ru) | N-ацетил-L-цистеин для применения в экстракорпоральном оплодотворении | |
| JP2019535830A5 (enExample) | ||
| EP1847274A1 (en) | Association of phenylbutyrate, ATRA and cytidine and its use in anti-tumour therapy |